Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of imiquimod in the management of lentigo maligna.
Daude M, Dinulescu M, Nguyen JM, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis MG, Bossard C, Vergier B, Khammari A, Dréno B. Daude M, et al. Among authors: leccia mt. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1785-1791. doi: 10.1111/jdv.19141. Epub 2023 May 6. J Eur Acad Dermatol Venereol. 2023. PMID: 37114291 Clinical Trial.
Thirty years of promoting sun safety in France: The messages are heard but not followed!
Passeron T, Lim HW, Goh CL, Kang HY, Ribeyre C, Demessant-Flavigny AL, Le Floc'h C, Kerob D, Krutmann J, Comte C, Dreno B, Leccia MT. Passeron T, et al. Among authors: leccia mt. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):e306-e309. doi: 10.1111/jdv.19543. Epub 2023 Nov 14. J Eur Acad Dermatol Venereol. 2024. PMID: 37915260 No abstract available.
Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Hazard M, Duval F, Dutriaux C, Beylot-Barry M, Pham-Ledard A, Quereux G, Amini-Adle M, Heidelberger V, Aubin F, Saint-Jean M, Nardin C, Abed S, Leccia MT, Mansard S, Prey S, Khammari A, Dréno B, Gérard E. Hazard M, et al. Among authors: leccia mt. J Neurol. 2024 Mar;271(3):1473-1482. doi: 10.1007/s00415-023-12105-2. Epub 2023 Dec 6. J Neurol. 2024. PMID: 38052771 No abstract available.
When to stop immunotherapy for advanced melanoma: the emulated target trials.
Amiot M, Mortier L, Dalle S, Dereure O, Dalac S, Dutriaux C, Leccia MT, Maubec E, Arnault JP, Brunet-Possenti F, De Quatrebarbes J, Granel-Brocard F, Gaudy-Marqueste C, Pages C, Stoebner PE, Saiag P, Lesimple T, Dupuy A, Legoupil D, Montaudié H, Oriano B, Lebbe C, Porcher R. Amiot M, et al. Among authors: leccia mt. EClinicalMedicine. 2024 Dec 4;78:102960. doi: 10.1016/j.eclinm.2024.102960. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39717261 Free PMC article.
Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.
Le Brun IC, Dalle S, Mortier L, Dereure O, Rat SD, Dutriaux C, Leccia MT, Legoupil D, Montaudié H, De Quatrebarbes J, Gaudy-Marqueste C, Maubec E, Saiag P, Pagès C, Possenti FB, Granel-Brocard F, Porcher R, Lefevre W, Lebbé C, Kempf E. Le Brun IC, et al. Among authors: leccia mt. Cancer. 2024 Dec 8. doi: 10.1002/cncr.35679. Online ahead of print. Cancer. 2024. PMID: 39645590
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab versus nivolumab in a real-world setting.
Karine B, Mortier L, Dereure O, Dalac S, Montaudié H, Legoupil D, Dutriaux C, De Quatrebarbes J, Maubec E, Leccia MT, Granel-Brocard F, Brunet-Possenti F, Arnault JP, Gaudy-Marqueste C, Pages C, Saiag P, L'orphelin JM, Zehou O, Lesimple T, Allayous C, Porcher R, Oriano B, Dalle S, Lebbé C. Karine B, et al. Among authors: leccia mt. Br J Dermatol. 2024 Nov 28:ljae470. doi: 10.1093/bjd/ljae470. Online ahead of print. Br J Dermatol. 2024. PMID: 39605282
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.
Macaire C, Lefevre W, Dalac S, Montaudié H, Legoupil D, Dereure O, Dutriaux C, Leccia MT, Aubin F, Grob JJ, Saiag P, De Quatrebarbes J, Maubec E, Lesimple T, Granel-Brocard F, Mortier L, Dalle S, Lebbé C, Prod'homme C. Macaire C, et al. Among authors: leccia mt. Melanoma Res. 2024 Nov 11;35(1):50-9. doi: 10.1097/CMR.0000000000000973. Online ahead of print. Melanoma Res. 2024. PMID: 39527777 Free PMC article.
188 results